Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary intracranial Central Nervous System (CNS) atypical teratoid/rhabdoid tumor OR~* Tumor tissue that possesses the INI-1 gene mutation~* No metastases that disseminate outside the CNS by abdominal and chest computer tomography (CT) scans, kidney imaging, and bone marrow biopsy~  * No obstruction of cerebrospinal fluid (CSF) flow by CSF flow study~* Definitive surgical resection of tumor within the past 35 days~PATIENT CHARACTERISTICS:~Age~* 18 and under~Performance status~* Karnofsky 50-100% OR~* Lansky 50-100%~Life expectancy~* Not specified~Hematopoietic~* Hemoglobin \> 10 g/dL~* Absolute neutrophil count \> 1,000/mm\^3~* Platelet count \> 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 mg/dL~* SGPT \< 10 times normal~Renal~* Creatinine ≤ 1.5 times normal~Other~* Willing to have placement of central venous access line~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Prior steroids allowed~Radiotherapy~* No prior radiotherapy~Surgery~* See Disease Characteristics~Other~* No other prior or concurrent investigational agents~* Concurrent anticonvulsant agents allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Multi-agent Intrathecal and Systemic CT with RT (mod IRS III) (Type: EXPERIMENTAL): Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)~Induction Chemotherapy: CT backbone of the IRS-III regimen \[vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)\] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged \<3y received focal RT (3D conformal or intensity-modulated delivery). Pts \>3y w/ M+ dz rcvd craniospinal irradiation.~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).